Slide 1: Results Presentation for the full year ended 30 June 2026
18 August, 2026 Melbourne, Australia Results Presentation for the full year ended 30 June 2026 CSL Limited (ASX:CSL; USOTC:CSLLY) Please find attached the slides for the presentation on the full year results that will be given by the Chief Executive Officer and Chief Financial Officer shortly. The l
Slide 2: 2026 Full Year Results
Tim, patient living with Hemophilia A Gordon Naylor Ken Lim 2026 Full Year Results Interim Chief Executive Officer & Managing Director Chief Financial Officer 18 August 2026
Slide 3: Important Notice and Disclaimer
IMPORTANT NOTICE AND DISCLAIMER This presentation contains summary information about CSL Limited (ACN 051 588 348) and The forward-looking statements involve known and unknown risks, its related bodies corporate (together, CSL) and CSL's activities as at the date of this uncertainties and assumption
Slide 4: CEO Overview
CEO Overview Gordon Naylor Interim CEO & Managing Director 3
Slide 5: FY26 a reset year
FY26 a reset year • Interim CEO appointed to accelerate CSL’s strategic transformation • Enhanced focus on commercial execution • Operational simplification and efficiency • Transformation program Restructuring initiatives on track Driving cost savings and disciplined reinvestment • Positioned t
Slide 6: FY26 Performance
FY26 performance FY26 Performance1 • Consistent with May 2026 update • Reported results include one-off pre-tax Revenue $15.8b 1% restructuring costs of $0.8b and impairment and related costs of $7.1b Underlying NPATA2,3 $3.1b 2% • Robust Ig demand Underlying NPAT7 $2.8b 3% • Strong uptake of ANDEMB
Slide 7: CSL Behring Revenue $11,387m
Revenue $11,387m 1% 1 Therapy Revenue ($m) Change1 Commentary Major Brands • Medicare Part D impact Ig 6,248 - • Channel inventory normalised • 2H up 7%1 on PCP, up 4% on TP1 • Government cost containment measures in China Albumin 1,115 (17%) • Expanded China footprint and Baheal partnership • 2H do
Slide 8: CSL Behring Portfolio execution and operational highlights
Portfolio execution Operational highlights • Renewed focus on plasma collection • Robust underlying Ig demand efficiency • Investments in field force in US & China Continued reduction in CPL • China albumin market stabilising Closure of underperforming centres Price declining at a slower rate
Slide 9: CSL Vifor Revenue $2,379m
Revenue $2,379m 3%1 Therapy Revenue ($m) Change1 Commentary Major Brands • VELPHORO® – TDAPA inclusion led to strong growth in 1H a Nephrology Dialysis 1,036 18% • 2H down 8%1 on TP ahead of expiry of TDAPA on 31 Dec 2026 b • FILSPARI® – strong patient uptake in launch markets Nephrology 330 17% • V
Slide 10: CSL Vifor Portfolio dynamics and operational highlights
Portfolio dynamics Operational highlights • Significant portfolio headwinds • Integration with CSL Behring commercial & medical affairs • Generic entrants in US market, challenging INJECTAFER® • Allocation of resources from CSL Vifor to CSL Behring • Continued generic competition in iron in Europe •
Slide 11: CSL Seqirus Revenue $2,031m
Revenue $2,031m 8%1 Therapy Revenue ($m) Change1 Commentary Major Brands • Only global company to grow year over year Adjuvanted Egg 968 5% in seasonal influenza revenue • Success of RWE strategy for FLUCELVAX® Cell Culture 503 5% and FLUAD® • Successful launches in Germany and France Egg Based 107
Slide 12: CSL Seqirus Portfolio execution and operating highlights
Portfolio execution Operating highlights • Differentiation strategy driving • Operational separation complete outperformance and market share gains in • Leveraging RWE strategy for FLUCELVAX® US & EU • Enhanced recommendations achieved for • Geographic expansion FLUAD® in the Republic of Ireland, Fr
Slide 13: Financials
Financials Ken Lim CFO CSL
Slide 14: CSL Group Financial highlights
CSL Group Financial highlights US$ millions FY25 Reported FY26 Reported FY26 at CC 1 Change % 1 Cashflow Total Revenue 15,558 15,797 15,371 (1%) • Strong cashflow Gross Profit4 8,443 8,454 8,269 (2%) GP %4 54.3% 53.5% 53.8% R&D Sales & Marketing4 (1,616) (1,691) (1,642) (2%) Operating Result4 6,827
Slide 15: Bridge to underlying performance
Bridge to underlying performance FY25 FY26 FY26 Change Reported Reported @CC %1 NPATA2,3 $3,219m $3,098m $3,142m (2%) Acquired intellectual property ($307m) ($322m) ($322m) (5%) amortisation (post-tax) NCI share of the above $60m $61m $61m 2% adjustments Underlying NPAT to CSL $2,972m $2,837m $2,881
Slide 16: Segment Financial highlights
Segment Financial highlights CSL Behring CSL Vifor CSL Seqirus Change Change Change 1 1 1 US$ millions reported FY26 % at CC FY26 % at CC FY26 % at CC Sales 11,087 (1%) 2,316 2% 1,809 (7%) Other Revenue 300 32% 63 71% 222 (17%) Total Revenue 11,387 (1%) 2,379 3% 2,031 (8%) Gross Profit4 5,648 (2%) 1
Slide 17: Strong progress on transformation initiatives
Strong progress on transformation initiatives Annual pre-tax cost savings • FY26 one-off pre-tax restructuring costs $799m* • FY26 cost savings delivered above target Up to ~$550m • Majority of savings across R&D, Commercial & Medical and Operations $400m • Disciplined approach to reinvestment ~$3
Slide 18: Impairments
Impairments FY26 $7.1b (1H $1.6b, 2H $5.5b) Key components of non-cash impairment and related charges for 2H26 • Change in competitor dynamics • Generic competition CSL VIFOR $4.1b • VELPHORO® TDAPA conclusion • TAVNEOS® marketing authorisation revoked • Goodwill • Primarily PPE impairments related
Slide 19: Capital Expenditure
Capital Expenditure • FY26 capex $766m in line with US$m % of Revenue expectations 1,400 16% 14% • Investment in Ig capacity at 1,200 Kankakee commenced 12% 1,000 10% • FY27 capex anticipated to 800 8% be ~$1b +/- $100m 600 6% 400 4% 200 2% - 0% FY20 FY21 FY22 FY23 FY24 FY25 FY26 Capex 18
Slide 20: Balance Sheet
Balance Sheet • Strong cash flow has significantly de-levered the Balance Sheet US$b Net Debt/EBITDA • Sufficient capacity to support 11.0 2.7 x 2.2 x 3.0 investment in growth 2.5 opportunities 10.0 1.8 x 1.8 x 2.0 • Leverage within target range of 1.5 1.5x – 2.0x 9.0 1.0 • Dividend maintained 0.5 •
Slide 21: CEO Overview
CEO Overview Gordon Naylor Interim CEO & Managing Director 20
Slide 22: FY27 Outlook (at FY26 FX rates)
FY27 Outlook (at FY26 FX rates) Behring and Seqirus return to growth; Vifor headwinds CSL Behring CSL Seqirus • Mid-single digit revenue growth • Low single digit revenue growth Ig growth in line with market: mid- Momentum in new markets and to-high single digits targeted customer segments Con
Slide 23: CSL Contacts
CSL Contacts Michelle Rees Investor Relations +61 410 600 745 michelle.rees@csl.com.au Bernard Ronchi Investor Relations +61 431 060 964 bernard.ronchi@csl.com.au Jimmy Baker Investor Relations +61 450 909 211 jimmy.baker@csl.com.au
Slide 24: Appendix
Appendix 23
Slide 25: Notes
Notes Constant Currency (#) Constant currency removes the impact of exchange rate Summary NPAT (Loss) attributable to members of Footnotes parent entity US$m movements to facilitate comparability of operational performance for the Group. This is done in three parts: a) by converting the current year
Slide 26: Appendix A: CSL Behring Key Products
Appendix A CSL Behring Key Products CSL Behring Therapy Group Sales $m PCP Change1 % FY26 Revenue By Therapy Group $m Privigen IVIG 4,017 (1%) IVIG $4,081 36% Hizentra SCIG 2,167 2% SCIG $2,167 19% Albumin Albumin 1,115 (17%) Haemophilia $1,515 13% Idelvion Haemophilia 874 1% CSL Albumin $1,115 10%
Slide 27: Appendix B: CSL Vifor & CSL Seqirus Key Products
Appendix B CSL Vifor & CSL Seqirus Key Products Sales Change1 FY26 Revenue By Therapy Group $m CSL Vifor Therapy Group $m % Ferinject/Injectafer Iron 653 (19%) Mircera Nephrology: Dialysis 578 2% Iron $915 38% Velphoro Nephrology: Dialysis 393 51% Nephrology: CSL $1,036 44% Veltassa Nephrology: Non-
Slide 28: Appendix C: FY26 Impairment Bridge
Appendix C FY26 Impairment Bridge Net Attributable Attributable $m Impairment* Tax of tax to NCI to CSL CSL Vifor Goodwill 1,700 Ferinject IP 1,548 Venofer IP 738 Mircera IP 301 Velphoro IP 175 Tavneos IP and associated expenses 166 Other intangibles 241 CSL Vifor Intangibles (inc. Goodwill) 4,869 (
Slide 29: Appendix D: NCI
Appendix D NCI CSL Vifor sales via VFMCRP by therapy area Nephrology – Dialysis ~70% Nephrology – Non-Dialysis ~40% Iron ~20% ~45% of total Vifor sales Based on FY26 sales 28
Slide 30: Appendix E: NPATA to NPAT Bridge
Appendix E NPATA2,3 to NPAT Bridge FY26 Bridge $M CSL NCI Total Underlying NPATA2,3 3,098 238 3,336 less: IP amortisation (307) (72) (379) add: tax impact 46 10 57 IP amortisation (post tax) (261) (62) (322) Allocation of FY26 pre-tax Underlying NPAT7 2,837 176 3,014 amortisation across segments Pre
Slide 31: CSL R&D Portfolio – FY26
CSL R&D Portfolio — FY26 e) Oo © Phasell Phase III Registration/Post-Registration CSL787 HIZENTRA® I HIZENTRA® FILSPARI®(Sparsentan) I ANDEMBRY® | Nebulized lo (SClg} 20% Liquid SClg) 20% Liquid Dual ET, & ATyantagonist Anti-Fxlla mAb HAE) (IgAN) FLUCELVAX? Trivalent (SID) J ‘Anumigilimab: | PRIVIGE
Slide 32: Glossary
Glossary aTIVc Adjuvanted Cell-based Trivalent Influenza Vaccine CC Constant Currency CPL Cost Per Litre CV Cardiovascular ESKD End Stage Kidney Disease HAE Hereditary Angioedema IG Immunoglobulin IDN Integrated Delivery Network IP Intellectual Property IVIG Intravenous Immunoglobulin NCI Non-Contro